Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Tarsus Pharmaceuticals, Inc.
TARS
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.6B
$64.84
▲ +6.49%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$38.51 - $85.25
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 50.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized disease-targeted therapeutic development
- Advanced clinical-stage product pipeline
- Focused research in underserved medical conditions
- Proprietary lotilaner technology platform
Bear Case
2 risks
- Low volatility (beta 0.5).
- Growth premium of 1.4x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Turning profitable
Expanding ophthalmology treatment market
Value
Growth premium of 1.4x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Weak
-13.2% over 3m
Quality
Excellent
High-growth business (129% revenue growth, 90% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying TARS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 29, 2026
MAY 6, 2026
Reported EPS of -$0.16 vs -$0.40 consensus (+60.0% surprise). Revenue of $162.1M vs $149.6M expected (+8.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+60.0%
Next: Apr 29, 2026
Revenue trend · last 8Q
—
—
+408%
+184%
+152%
+147%
+128%
+107%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$40.8M
$48.1M
$66.4M
$78.3M
$102.7M
$118.7M
$151.7M
$162.1M
Margins · last 8Q
Gross
—
Operating
—
Profit
-4.3%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · May 4, 2026